BACKGROUND AND AIMS: Coeliac disease (CD) is an enteropathic disorder characterised by a strong association with major histocompatibility complex (MHC) heterodimer HLA-DQ2. It has been suggested that other HLA class I genes in combination with DQ may also contribute to CD susceptibility. The aim of this study was to investigate whether other candidate genes modify the risk of developing different clinical forms of CD. PATIENTS AND METHODS: We studied 133 Spanish coeliac patients, divided according to their clinical presentation into typical and atypical groups, and 116 healthy controls. All were typed by polymerase chain reaction-sequence specific primers (PCR-SSP) at HLA-B, DRB1, DQA1, and DQB1 loci and for exon 5 of the MHC class I chain related gene A (MICA). RESULTS: No differences were found in the frequency of the DQA1*0501/DQB1*0201 heterodimer in either group. The risk of typical CD was significantly associated with the DR7/DQ2 haplotype (p(c)=0.02, odds ratio (OR)=3.4, ethiological fraction (EF)=0.4). Extended haplotype (EH) 8.1 (B8/DR3/DQ2) was found to be overrepresented in the atypical form compared with the typical form (p(c)=0.001, OR=4.19, EF=0.56). The trinucleotide repeat polymorphism MICA-A5.1 was found to be increased in the atypical group of patients compared with the typical group (p(c)=0.00006, OR=8.63, EF=0.81). This association was independent of linkage disequilibrium with EH8.1 as this was also found to be increased in EH8.1 negative atypical patients compared with the typical group (p(c)=0.004, OR=6.66, EF=0.56). CONCLUSIONS: Our results showed that the risk of developing typical forms of CD was associated with DR7/DQ2 haplotype, and the presence of B8/DR3/DQ2 was significantly increased in atypical patients. In these, the MICA-A5.1 allele confers an additive effect to the DR3/DQ2 haplotype that may modulate the development of CD.
BACKGROUND AND AIMS: Coeliac disease (CD) is an enteropathic disorder characterised by a strong association with major histocompatibility complex (MHC) heterodimer HLA-DQ2. It has been suggested that other HLA class I genes in combination with DQ may also contribute to CD susceptibility. The aim of this study was to investigate whether other candidate genes modify the risk of developing different clinical forms of CD. PATIENTS AND METHODS: We studied 133 Spanish coeliac patients, divided according to their clinical presentation into typical and atypical groups, and 116 healthy controls. All were typed by polymerase chain reaction-sequence specific primers (PCR-SSP) at HLA-B, DRB1, DQA1, and DQB1 loci and for exon 5 of the MHC class I chain related gene A (MICA). RESULTS: No differences were found in the frequency of the DQA1*0501/DQB1*0201 heterodimer in either group. The risk of typical CD was significantly associated with the DR7/DQ2 haplotype (p(c)=0.02, odds ratio (OR)=3.4, ethiological fraction (EF)=0.4). Extended haplotype (EH) 8.1 (B8/DR3/DQ2) was found to be overrepresented in the atypical form compared with the typical form (p(c)=0.001, OR=4.19, EF=0.56). The trinucleotide repeat polymorphism MICA-A5.1 was found to be increased in the atypical group of patients compared with the typical group (p(c)=0.00006, OR=8.63, EF=0.81). This association was independent of linkage disequilibrium with EH8.1 as this was also found to be increased in EH8.1 negative atypical patients compared with the typical group (p(c)=0.004, OR=6.66, EF=0.56). CONCLUSIONS: Our results showed that the risk of developing typical forms of CD was associated with DR7/DQ2 haplotype, and the presence of B8/DR3/DQ2 was significantly increased in atypical patients. In these, the MICA-A5.1 allele confers an additive effect to the DR3/DQ2 haplotype that may modulate the development of CD.
Authors: C Catassi; I M Rätsch; E Fabiani; M Rossini; F Bordicchia; F Candela; G V Coppa; P L Giorgi Journal: Lancet Date: 1994-01-22 Impact factor: 79.321
Authors: S Gonzalez; J Martinez-Borra; J C Torre-Alonso; S Gonzalez-Roces; J Sanchez del Río; A Rodriguez Pérez; C Brautbar; C López-Larrea Journal: Arthritis Rheum Date: 1999-05
Authors: G Gambelunghe; A Falorni; M Ghaderi; S Laureti; C Tortoioli; F Santeusanio; P Brunetti; C B Sanjeevi Journal: J Clin Endocrinol Metab Date: 1999-10 Impact factor: 5.958
Authors: Segundo González; Sandra Rodríguez-Rodero; Jesús Martínez-Borra; Antonio López-Vázquez; Luis Rodrigo; Carlos López-Larrea Journal: Immunogenetics Date: 2003-03-06 Impact factor: 2.846
Authors: Markéta Fojtíková; Peter Novota; Pavlína Cejková; Satu Pešičková; Dana Tegzová; Marie Cerná Journal: Rheumatol Int Date: 2010-03-30 Impact factor: 2.631
Authors: Akane Ide; Sunanda R Babu; David T Robles; Tianbao Wang; Henry A Erlich; Teodorica L Bugawan; Marian Rewers; Pamela R Fain; George S Eisenbarth Journal: J Clin Immunol Date: 2005-07 Impact factor: 8.317
Authors: Andrew S Louka; Benedicte A Lie; Bente Talseth; Henry Ascher; Johan Ek; Audur H Gudjónsdóttir; Ludvig M Sollid Journal: Immunogenetics Date: 2003-07-04 Impact factor: 2.846
Authors: B Admou; L Essaadouni; K Krati; K Zaher; M Sbihi; L Chabaa; B Belaabidia; A Alaoui-Yazidi Journal: Gastroenterol Res Pract Date: 2012-07-03 Impact factor: 2.260